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Abstract
Background: Duchenne muscular dystrophy (DMD) is the most commonly inherited neuromuscular disease.
Therapeutic agents for the treatment of rare disease, namely “orphan drugs”, have recently drawn the attention of
researchers and pharmaceutical companies. To ensure the successful conduction of clinical trials to evaluate novel
treatments for patients with rare diseases, an appropriate infrastructure is needed. One of the effective solutions for
the lack of infrastructure is to establish a network of rare diseases.
Methods: To accomplish the conduction of clinical trials in Japan, the Muscular dystrophy clinical trial network
(MDCTN) was established by the clinical research group for muscular dystrophy, including the National Center of
Neurology and Psychiatry, as well as national and university hospitals, all which have a long-standing history of
research cooperation.
Results: Thirty-one medical institutions (17 national hospital organizations, 10 university hospitals, 1 national center,
2 public hospitals, and 1 private hospital) belong to this network and collaborate to facilitate clinical trials. The Care
and Treatment Site Registry (CTSR) calculates and reports the proportion of patients with neuromuscular diseases in
the cooperating sites. In total, there are 5,589 patients with neuromuscular diseases in Japan and the proportion of
patients with each disease is as follows: DMD, 29 %; myotonic dystrophy type 1, 23 %; limb girdle muscular
dystrophy, 11 %; Becker muscular dystrophy, 10 %. We work jointly to share updated health care information and
standardized evaluations of clinical outcomes as well. The collaboration with the patient registry (CTSR), allows the
MDCTN to recruit DMD participants with specific mutations and conditions, in a remarkably short period of time.
Conclusion: Counting with a network that operates at a national level is important to address the corresponding
national issues. Thus, our network will be able to contribute with international research activity, which can lead to
an improvement of neuromuscular disease treatment in Japan.
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Background
Duchenne muscular dystrophy (DMD) is the most com-
monly inherited neuromuscular disease, affecting ap-
proximately 1 out of 3600 to 6000 live newborn boys.
Many of the drugs and medical devices developed for
the treatment of neuromuscular diseases are classified as
orphan drugs [1]. In Japan, orphan drugs and medical
devices are defined as “those intended for use in less
than 50 000 patients, for which there is a high medical
need.” Regarding therapeutic agents for rare diseases,
orphan drugs have not been actively developed because
they represent uncertain profit margins for pharmaceu-
tical companies. However, this situation has changed
drastically. Recently, various therapeutic approaches
have been developed, and the conduction of clinical
trials have either shown or are expected to show the
efficacy of these therapeutic agents and strategies, such
as antisense oligonucleotide drug and read-through the-
rapy, for DMD treatment [2].
In conducting clinical research of rare diseases, patient
recruitment, accurate evaluation and standardized treat-
ment are important factors for assessing the effect of
treatment. To recruit a sufficient number of patients, an
international clinical research design is often chosen,
and the appropriate infrastructure is needed to conduct
this type of research.
Two well-known global networks have been organized
to facilitate the study of novel therapies for neuromuscu-
lar diseases, including the TREAT-NMD in the European
Union and the Cooperative International Neuromuscular
Research Group (CINRG) in the United States. Each
network has its own characteristic features, and is in regu-
lar and close communication with the other. The CINRG
was established in 1999, as a consortium of medical and
academic investigators from academic and research cen-
ters, to contribute with the improvement of therapeutic
agents aimed for the treatment of neuromuscular diseases
by conducting clinical observation studies and performing
well-designed controlled clinical trials. Additionally, the
coordinating center works as an academic research
organization (ARO). Twenty-eight sites from 12 countries
are collaborating for this purpose [3], and those sites
are located at medical institutions employing specia-
lists that care for patients with neuromuscular disease
in each country. TREAT-NMD was established in 2007 as
a network focused on the neuromuscular field that pro-
vides the infrastructure for conducting clinical research,
such as patient registries, standardization of treatment,
establishment of outcome measures, communication
between patients, researchers, companies and regulation
agencies for the purpose of ensuring that the most
promising new therapies reach patients as quickly as pos-
sible. Members from 43 countries are gathered for this
alliance [4, 5].
Japan has a long-standing history of treatment and
care of patients with neuromuscular dystrophy. Since
1964, wards specifically designed to care for patients
with neuromuscular dystrophy have been established in
national hospitals, and these wards are managed by the
Japanese government. This practice has gradually become
widespread throughout Japan based on the government’s
ruling. National hospitals were then reorganized in the
National Hospital Organization (NHO) in 2004. The
Ministry of Health, Labour and Welfare (MHLW) later
designated the National Center of Neurology and Psy-
chiatry (NCNP) to organize research groups for the treat-
ment and medical care of patients with neuromuscular
dystrophy in those hospitals. One of these research groups
has performed annual surgeries and maintained an inte-
grated database on neuromuscular dystrophy patients
since 1999 [6]. This activity contributed to the improve-
ment of treatment and care of patients with neuromus-
cular dystrophy, in particular, with the introduction of
ventilators to the wards devoted to the care of these
patients. Consequently, the mean age of death among
patients with DMD in those specific wards was 17 years in
1980, 27.6 years in 2000 and 35.1 years in 2010. Ventila-
tors were also distributed to the patients who were cared
for at their own homes.
Muscular Dystrophy Clinical Trial Network (MDCTN)
was established in 2012 as the result of activities of the
clinical research group for neuromuscular dystrophy,
including the NCNP and national hospitals, which have
the specific wards and outpatient clinic to treat patients
with neuromuscular dystrophy and the university hospi-
tals. This is the first clinical research network for neuro-
muscular diseases in Asia, and is also the first clinical trial
network for rare diseases in Japan aiming to expedite and
ensure the success of clinical research for rare diseases.
Methods
Organizational structure
The structure of this network is shown in Fig. 1. The
headquarters of this network are located at the Transla-
tional Medical Center (TMC), NCNP in Tokyo, Japan.
The development of this network was supported by the
Intramural Research Grant (23–6, 26–6) for Neurological
and Psychiatric Disorders, provided by the NCNP. This
network consists of 31 cooperative sites, and consists of a
steering committee, specific working groups, and a coor-
dinating office. The steering committee members include
specialists in neuromuscular disease, 3 selected represen-
tatives from each cooperative sites, a director of the
NCNP hospital, a director of the TMC at the NCNP, and
a representative from the coordinating office. Any domes-
tic medical institutions that are interested in clinical trials
for neuromuscular diseases, and accept to complete the
annual survey and non-disclosure agreement, are able to
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join in this network as cooperative sites. The coordinating
office is the hub of this network, and collaborates with
patient registries for the exchange of information. The
coordinating office facilitates study participant recruit-
ment. Additionally, it has been engaged in a consultation
with clients and the coordination of processes related to
the conduction of clinical research trials between re-
searchers and pharmaceutical companies. The TMC will
support these network activities and provide the experts,
such as statisticians, project managers, data managers,
and monitors, for these clinical research or trials, if neces-
sary. The specific working groups are aimed at facilitating
clinical research or trials. The outcome measure working
group is now actively participating in a standardization of
clinical outcome measures by verifying the outcome
measures that can reflect the physical conditions of
patients more accurately and ultimately evaluate the effect
of interventions or therapies. This working group consists
of medical doctors, physical therapists, and clinical coor-
dinators, which have regular discussions aimed at looking
for more sensitive and accurate outcome measures for
multi-institutions by offering training courses, workshops
and seminars for cooperative sites.
Structure of the registry forms
Our site registry questionnaires are based on the Care and
Treatment Site Registry (CTSR) of the TREAT-NMD [7],
which will allow an easier collaboration between our
network and TREAT-NMD in the future. In the list of the
proportion of patient with each disease included in ques-
tionnaires for each coordination site, we added Fukuyama
type neuromuscular dystrophy (FCMD), which is diag-
nosed relatively frequently in some Asian countries, such
as Japan. We also added UDP-N-acetylglucosamine-2-
epimerase/N-acetylmannosamine kinase (GNE) myopathy,
and mitochondrial diseases to the original list proposed by
TREAT-NMD. Conversely, hereditary motor neuropathy,
congenital myasthenic syndrome, and muscular channelo-
pathies have been excluded from our list because these
diseases are rare in Japan and have not been included
in the annual survey applied to the specific neuromus-
cular dystrophy wards in NHO. These questionnaires
consist of the following items: basic information of each
site, the total number of affected patients and number of
patients diagnosed with each type of neuromuscular
dystrophy, research activity, diagnostic techniques and
equipment, clinical trial experience, and a list of available
medical specialists for clinical trials. These question-
naires are annually sent and answers are collected on-
line and manually curated by the coordinating office
of the MDCTN.
The management of patient recruitment
Pharmaceutical industries or researchers contact the
coordinating office of MDCTN to recruit participants
into their clinical trials via collaboration with patient
Fig. 1 Structure of the Muscular dystrophy clinical trial network (MDCTN). This network consists of the steering committee, coordinating sites,
working group and coordinating office. The coordinating office is the hub that communicates between clients, patient registry, and cooperative
sites. The TMC supports research activities if necessary, and it provides protocol management. The MDCTN also includes a data manager, protocol
development support, biostatistics analyses, and monitoring. Abbreviations: MDCTN, Muscular dystrophy clinical trial network; NCNP, National
Center of Neurology and Psychiatry; TMC, Translational medical center
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registries, such as the Registry of Muscular Dystrophy
(Remudy) [8]. Then, the coordinating office will contact
the patient registry office and ask to send recruitment
letters to candidates according to their clinical and
genetic data base. Candidates would send responses to
the coordinating office, after being contacted as potential
participants. Our coordinating office asks them to
consult their doctors to confirm that they truly fit the
inclusion and exclusion criteria of the proposed study. If
they fulfill the criteria, the coordinating office introduces
patients to the representatives of the institution where
the clinical trial will be conducted (Fig. 2).
The management of the feasibility inquiry
The operation of feasibility inquiries from pharmaceu-
tical companies or researchers is one of the most impor-
tant tasks of the coordinating center. Under the contract
of confidentiality, the coordinating office collects the
information regarding feasibility inquiries of their clinical
trials or studies. Clients are able to choose the sites based
on the information provided by the office.
Regular meeting opportunities
For the exchange of opinions and information regarding
updated research progress and current and promising
therapies, we conduct an annual workshop with network
members, representatives of pharmaceutical companies,
patient advocacy groups, regulatory agencies, and anyone
interested in MDCTN activities. We also have regular
meetings with representatives from the cooperative sites
to maintain a constant flow of communication among the
sites. As a part of our working group activities, we conduct
seminars for Physical Therapists (PT) and clinical research
coordinators (CRCs) to standardize clinical evaluations.
Ethics
This network does not have a central Institutional Review
Board (IRB) system yet. The IRB of each cooperative site
has to review the protocols for clinical research planned
to be conducted at each institution. The data presented
herein are not data, rather they consist of inquiries made
to the cooperative sites.
Results
Cooperative sites
The MDCTN was established in December 2012, and a
total of 31 institutions have registered since then: 17
national hospital organizations (NHO), 10 university
hospitals, 1 national center, 2 public hospitals, and 1
private hospital. These institutions are distributed in
almost all areas of Japan (Fig. 3).
One of the university hospitals organized their own
clinical network for neuromuscular dystrophy in its
district and registered the MDCTN as the representative
of their network. Most of clinical departments who have
registered as cooperative sites of MDCTN are either
departments of neurology, pediatrics or pediatric neu-
rology. One orthopedic department from a university
hospital, characterized for the surgical treatment of sco-
liosis in patients with neuromuscular diseases, has also
registered. One site did not submit their data in time, and
thus, the data of that site were excluded. The data of the
CTSR is an aggregate of data from 30 sites. Three of the
cooperative sites have already registered in the CTSR of
the TREAT-NMD.
Description of site registry data
Thirty out of 31 cooperating sites answered the following
queries between September 2013 and February 2014.
Patient proportion
There is a total 5,589 patients with neuromuscular dis-
eases (Fig. 4). In decreasing order, the diseases are listed
as follows: DMD, 29 %; myotonic dystrophy type 1
(DM1), 23 %; Limb girdle muscular dystrophy (LGMD),
11 %; Becker muscular dystrophy (BMD), 10 %; faciosca-
pulohumeral muscular dystrophy, 7 %; and FCMD, 5 %.
Less than 1 % of patients registered have DM2 and
Pompe disease. Approximately a half of DMD and two-
thirds of BMD patients have reached adulthood (Data
not shown). The current situation of each MDCTN sites,
Fig. 2 Patient recruitment pathway. First, the client (researcher or
pharmaceutical company) requests the patient recruitment to
Muscular dystrophy clinical trial network (MDCTN) coordinating
office. The coordinating office communicates with the patient
registry and sends recruitment letters to registered patients who
might the meet criteria. Through communications with patients and
their local doctor, participants are able to enter the clinical trial
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such as diagnostic techniques, clinical evaluation, medical
specialist availability, and clinical trial experience, are de-
scribed below and summarized in Fig. 5.
Diagnostic techniques
The diagnosis for dystrophinopathies (DMD and BMD),
such as multiplex ligation-dependent probe amplification
analysis, sequencing, and genetic tests for DM and FCMD
are covered by the national health insurance system in
Japan. There are medical institutions, including the NCNP,
which perform gene analysis for spinal muscular atrophy,
mitochondrial myopathy, or GNE myopathy.
Clinical evaluation
Timed tests, such as the 10-meter walking test, are largely
available in all the sites. However, many sites have less
experience in more complicated evaluations such as the
North Star Ambulatory Assessment. Twenty-five coopera-
tive sites can perform muscle biopsy. All sites can perform
muscle magnetic resonance imaging (MRI) and one third
of the sites can perform cardiac MRI as well.
Medical specialist availability
Certified child neurologists are available in 19 coopera-
tive sites, and certificated adult neurologists are available
in 28 sites. Pulmonologist, cardiologist, and geneticists/
genetic counselors are available in 23, 26, and 19 sites
respectively. Physical therapists are available in all sites.
Respiratory care for adult dystrophic patients is available
in 27 sites.
Clinical trial experience
Phase I, II, III, and IV clinical trials were experienced in
5 (17 %), 13 (43 %), 23 (77 %), and 15 (50 %) sites,
respectively. Four sites have engaged in sponsor-initiated
or investigator-initiated clinical trials of DMD. Clinical
research coordinators (CRC) are available in 21 sites
(data not shown).
Patient recruitment
We operated two investigator-initiated clinical trials
using Remudy for recruitment: “Exploratory Phase Trial
of NS-065/NCNP-01 in Duchenne muscular dystrophy”
(NCT02081625) and “Phase II Study of NPC-14 (Arbe-
kacin Sulfate) to Explore Safety, Tolerability, and Efficacy
in Duchenne Muscular Dystrophy” (NCT01918384).
Inquiries and support
Feasibility inquiry
One pharmaceutical company requested the coordina-
ting office to conduct feasibility inquiries regarding their
clinical trials. The MDCTN completed those inquiries
within 4 weeks.






Fig. 3 Map of the cooperative sites. Thirty-one sites have joined the Muscular dystrophy clinical trial network and are widespread across Japan.
Several urban sites are concentrated in the large cities, such as Tokyo and Osaka. (Source http://www.mdctn.jp/network.html)
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Meeting and education
Meeting opportunities, such as seminars and workshops,
are generally welcome, since these are valuable oppor-
tunities to exchange information with other healthcare
providers who are involved in neuromuscular disease
treatment, as well as pharmaceutical companies that
have developed cutting-edge drugs and devices for the
management of specific diseases, like DMD. Seminars
for PTs and CRCs are also great opportunities to engage
in discussions and communicate different experiences
regarding the treatment and care of patients with neuro-
muscular diseases. These seminars are also effective for
standardization of evaluations.
Discussion
Therapeutic agents for the treatment of rare disease are
called “orphan drugs” and have become the object of atten-
tion of researchers and pharmaceutical companies in recent
years. In 2012, the MHLW announced the 5-year Clinical
Trial Activation Plan for the purpose of stimulating clinical
research and trials in Japan. As part of that plan, relevant
aims were creating a system to operate the clinical trials
and establishing a patient registry of rare diseases [9]. To
achieve these objectives effectively and to promote clinical
trials and clinical research, collaboration was established
between the patient registry and MDCTN. A close
collaboration with the patients’ registry and standardization
of treatment and clinical evaluations among many local
sites is very important. It helps increase the availability and
accessibility to the latest treatment information and
increases the participation of patients with rare diseases
and their families in clinical research, regardless of their
area of residence. The Rare Diseases Clinical Research
Network, supported by the National Institutes of Health
(NIH), stated that the success of recruitment depends on
many approaches, such as contact registries, referrals from
patient advocacy groups, and enrollment of existing pa-
tients at consortium sites [10]. The MDCTN is the first
national network aimed at facilitating regular and successful
operations of clinical trials and research of neuromuscular
diseases that comprises medical sites with a long-standing
history of treatment for neuromuscular diseases in Asia.
When comparing our registered data to that in TREAT-
NMD CTSR, the data for the proportion of patients with
dystrophinopathy was similar. The ratio of LGMD is about
two-thirds of that registered in TREAT-NMD. The propor-
tions of DM1 and congenital muscular dystrophy (CMD)
are 23 % and 7 % (Fukuyama type congenital muscular dys-
trophy: FCMD 5 %, other CMD 2 %) respectively, which is
higher than the ratio in TREAT-NMD (17 % and 9 %, re-
spectively) [11]. There is a remarkably higher proportion of
patients with FCMD registered in MDCTN in than in
TREAT-NMD CTSR. FCMD is a characteristic neuromus-
cular disease in the Japanese and Asian populations [12].
Regarding the cooperative sites, over 70 % of the sites

























Fig. 4 Overall patient cohort of the MDCTN. From 30 out of 31 cooperative sites, 5,589 patients have been reported. This data were calculated based on
a rough estimate of the proportion of patients with each disease reported at each site. Abbreviations: MDCTN, Muscular dystrophy clinical trial network;
GNE, UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase; DM1 and 2, myotonic dystrophy type 1 and type 2; DMD, Duchenne muscular
dystrophy; LGMD, Limb-girdle muscular dystrophy; BMD, Becker muscular dystrophy; FCMD, Fukuyama type neuromuscular dystrophy; FSHMD,
Facioscapulohumeral muscular dystrophy; CM, Congenital myopathy; CMD, Congenital muscular dystrophy; mito, Mitochondrial myopathy
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suggest that they have enough potential to conduct
clinical trials. However, the MDCTN has two limitations
regarding the proportion of patients with each disease: the
accuracy of the numbers reported and quality of diagno-
ses. First, the proportion of each patient affected by
each neuromuscular disease might be overestimated,
especially in large urban areas. Because of the proxim-
ity of several sites, the registration of some patients
might be duplicated in different sites and reports. Sec-
ond, not all of the patients were genetically diagnosed
because genetically diagnostic techniques were not avail-
able at the time of their diagnosis. However, registry data of
MDCTN sites are still valuable for the conduction of clin-
ical trials because there are no previous data on the
infrastructural situation of clinical sites in Japan, such as
that of TREAT-NMD.
There are both differences and similarities between
MDCTN and other disease-specific networks, such as
CINRG and TREAT-NMD. The main differences between
MDCTN and the international networks are that MDCTN
is a domestic network, and not all its sites have vast clinical
research experience. Its main similarity with CINRG is that
the coordinating office works as an ARO. The main similar-
ities with TREAT-NMD are that both apply corroboration
with patient registries, standardization of treatment, and es-
tablish outcome measures. The MDCTN is equipped with
these functions, which are modified depending on the situ-
ation in Japan and are going to be improved.
Fig. 5 Available evaluations. This figure shows the number of sites, which provide the listed evaluations. This data were obtained from
30 out of 31 site reports
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In Japan, the MDCTN has conducted two patient
recruitments for clinical trials, as mentioned above.
Additionally, we have conducted one feasibility enquiry.
Basically, consent for research is based on the relation-
ship between the physicians, the patients, and their
family [13]. Before the potential participants join the clin-
ical trial through the recruitment process via the patient
registry, we have arranged for patients to be introduced to
the site by their treating physicians, with whom trust has
been already established. We believe that it is very difficult
to recruit the potential candidates through the system.
MDCTN has three advantages. The first one refers to
quick inquiries and patient recruitment. To achieve quick
inquiries and patient recruitment, a close communication
with the patient registry and having updated registry data
from all the sites are remarkably important. These data
will indicate the location of the patients, which is useful
for clinical research because it allows them to easily
recognize potential research partners. This can also trans-
late into less time and costs of recruitment for pharma-
ceutical companies. Additionally, showing the proportions
of patient with rare diseases and sites may create oppor-
tunities for the Japanese sites to participate in inter-
national clinical research.
The second advantage is to be able to share the infor-
mation of the latest research and clinical trials through
the meetings. The MDCTN covers most of the hospitals
in Japan with extensive experience in treating neuromus-
cular diseases. This makes it possible to provide equal
opportunities in terms of the latest research information
for the benefit of the patients.
There is no doubt that the support of a national network
in collaboration with a national patient registry is a power-
ful source of support for an international network, such as
TREAT-NMD and CINRG, by which clinical research for
neuromuscular diseases is being promoted energetically.
The conduction of global clinical trials is also very impor-
tant for the development of cutting-edge drugs and treat-
ments, especially for rare diseases. However, cooperative
sites are not equally participative all over the world. It may
be the case that only a few sites attend the activities from
some countries in Asia. This may result in those sites
gaining updated international, high-quality evaluation
method, research information and/or treatment, and the
rest of the sites may be left behind. MDCTN provides
resources such as meetings and educational opportu-
nities for health care providers, including PT and CRC.
Furthermore, this is a good opportunity to share the latest
information, treatment or evaluation for specific rare
diseases. We believe that this will contribute to
standardization among cooperating sites.
Ando et al. are reported that 15 % of multinational
clinical trials were operated in Asia or East Asia in 2012
[14]. In this area, the Asia Oceania Myology Center
(AOMC) provides opportunities for standardization of
treatment and basic research. The AOMC also provides
a forum for the discussion of issues related to their own
countries, as well as support to find solutions. Therefore,
it is clear that networks operating at a nation level, like
MDCTN, are necessary. Each country has different
issues that affect the conduction of clinical trials, such as
medical environment, drug approval processes and regu-
lations, and social systems, and thus, each country needs
to develop different plans and strategies to tackle these
issues. The MDCTN can serves as a model of a national
network. Additionally, we assure that the activity of im-
proving the national standards will contribute to improve
and facilitate international clinical research activities.
Conclusion
The MDCTN was established for the purpose of facili-
tating “the development of models of pharmaceuticals
and medical devices for rare diseases at a national level”
and to become an infrastructure for the support of
multi-institutional clinical research of promising drugs,
devices and health care modalities for the management
of rare disease, such as neuromuscular dystrophy. Shar-
ing updated health care information and standardized
evaluations among cooperative sites makes it possible to
activate qualified clinical research even if neuromuscular
dystrophy is a rare disease. A close collaboration with the
patient registry is important for recruitment of patients
with rare diseases. We consider that network activities at
a national level will contribute to successful international
clinical research with high quality outcomes and improve-
ment of patient care and treatment.
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